Table 1.
Baseline patient characteristics
| Variable | Schedule A (N = 32) n (%) | Schedule B (N = 32) n (%) | Total (N = 64) n (%) |
|---|---|---|---|
| Age | |||
| Median | 55.5 | 53.0 | 54.5 |
| Range | 25–74 | 24–81 | 24–81 |
| Mean ± SD | 52 ± 14.5 | 51 ± 15.5 | 51.5 ± 14.9 |
| Gender | |||
| Female | 14 (43.8%) | 10 (31.3%) | 24 (37.5%) |
| Male | 18 (56.3%) | 22 (68.8%) | 40 (62.5%) |
| ECOG performance score | |||
| 0 | 4 (12.5%) | 10 (31.3%) | 14 (21.9%) |
| 1 | 18 (56.3%) | 14 (43.8%) | 32 (50.0%) |
| 2 | 10 (31.3%) | 8 (25.0%) | 18 (28.1%) |
| 3 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 |
| Steroids | |||
| Yes | 22 (68.8%) | 21 (65.6%) | 43 (67.2%) |
| No | 6 (18.8%) | 11 (34.4%) | 17 (26.6%) |
| Missing | 4 (12.5%) | 0 | 4 (6.3%) |
| Anticonvulsants | |||
| Yes | 26 (81.3%) | 26 (81.3%) | 52 (81.3%) |
| No | 6 (18.8%) | 6 (18.8%) | 12 (18.8%) |
| Prior Nitrosoureas | |||
| Yes | 24 (75.0%) | 26 (81.3%) | 50 (78.1%) |
| No | 8 (25.0%) | 6 (18.8%) | 14 (21.9%) |
| Months since end of RT | |||
| <6 | 5 (15.6%) | 10 (31.3%) | 15 (23.4%) |
| 6–12 | 11 (34.4%) | 8 (25.0%) | 19 (29.7%) |
| >12 | 16 (50.0%) | 14 (43.8%) | 30 (46.9%) |
| Primary tumor resection | |||
| None | 0 | 0 | 0 |
| Biopsy | 11 (34.4%) | 9 (28.1%) | 20 (31.3%) |
| Subtotal | 14 (43.8%) | 14 (43.8%) | 28 (43.8%) |
| Total | 7 (21.9%) | 9 (28.1%) | 16 (25.0%) |
| Histology | |||
| Astrocytoma | 22 (68.8%) | 18 (56.3%) | 40 (62.5%) |
| Gliosarcoma | 0 | 0 | 0 |
| Oligodendroglioma | 4 (12.5%) | 5 (15.6%) | 9 (14.1%) |
| Oligoastrocytoma | 5 (15.6%) | 8 (25.0%) | 13 (20.3%) |
| Unknown | 1 (3.1%) | 1 (3.1%) | 2 (3.1%) |
| Grade | |||
| 1 | 0 | 0 | 0 |
| 2 | 2 (6.3%) | 6 (18.8%) | 8 (12.5%) |
| 3 | 8 (25.0%) | 6 (18.8%) | 14 (21.9%) |
| 4 | 21 (65.6%) | 19 (59.4%) | 40 (62.5%) |
| Unknown | 1 (3.1%) | 1 (3.1%) | 2 (3.1%) |